Molecular pathways: Overcoming radiation resistance by targeting DNA damage response pathways

Clinical Cancer Research

Volumn 21, Issue 13, 2015, Pages 2898-2904

  Morgan, Meredith A ^a   Lawrence, Theodore S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 2 ALLYL 1 [6 (1 HYDROXY 1 METHYLETHYL) 2 PYRIDINYL] 6 [4 (4 METHYL 1 PIPERAZINYL)ANILINO] 1H PYRAZOLO[3,4 D]PYRIMIDIN 3(2H) ONE; 2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; ANTINEOPLASTIC AGENT; AZ 32; AZD 6738; B 02; CARBOPLATIN; CC 115; KU 59403; LY 2606318; LY 2606368; MK 8776; NIRAPARIB; OLAPARIB; RADIOSENSITIZING AGENT; RI 1; SCR 7; SMI MCI 13E; UNCLASSIFIED DRUG; VE 821; VE 822; VELIPARIB; VX 970;

ARTICLE; CANCER RADIOTHERAPY; CELL CYCLE CHECKPOINT; CELL SURVIVAL; CHEMORADIOTHERAPY; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; HUMAN; IONIZING RADIATION; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION INJURY; RADIOSENSITIVITY; TUMOR CELL; DRUG EFFECTS; MOLECULARLY TARGETED THERAPY; NEOPLASMS; RADIATION TOLERANCE;

DNA DAMAGE; DNA REPAIR; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS;

EID: 84941966140     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-3229     Document Type: Article

References (58)

1. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011;11:393-410.
2. Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008;8:545-54.
3. Toulany M, Rodemann HP. Membrane receptor signaling and control of DNA repair after exposure to ionizing radiation. Nuklearmedizin 2010;49 Suppl 1:S26-30.
4. Formenti SC, Demaria S. Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys 2012;84:879-80.
5. Mladenov E, Magin S, Soni A, Iliakis G. DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy. Front Oncol 2013;3:113.
6. Groth P, Orta ML, Elvers I, Majumder MM, Lagerqvist A, Helleday T. Homologous recombination repairs secondary replication induced DNA double-strand breaks after ionizing radiation. Nucleic Acids Res 2012;40: 6585-94.
7. Goodarzi AA, Jeggo P, Lobrich M. The influence of heterochromatin on DNA double strand break repair: Getting the strong, silent type to relax. DNA Repair 2010;9:1273-82.
8. Shibata A, Conrad S, Birraux J, Geuting V, Barton O, Ismail A, et al. Factors determining DNA double-strand break repair pathway choice in G2 phase. EMBO J 2011;30:1079-92.
9. Flynn RL, Zou L. ATR: A master conductor of cellular responses to DNA replication stress. Trends Biochem Sci 2011;36:133-40.
10. Iliakis G, Dahm-Daphi J, Dikomey E. DNA repair and cell cycle regulation after ionizing irradiation. In: Molls M, Vaupel P, Nieder C, Anscher MS, editors. The impact of tumor biology on cancer treatment and multidisciplinary strategies. Berlin, Heidelberg: Springer-Verlag; 2009. p. 251-71.
11. Jeggo PA, Geuting V, Lobrich M. The role of homologous recombination in radiation-induced double-strand break repair. Radiother Oncol 2011; 101:7-12.
12. Ochi T, Blackford AN, Coates J, Jhujh S, Mehmood S, Tamura N, et al. DNA repair. PAXX, a paralog of XRCC4 and XLF, interacts with Ku to promote DNA double-strand break repair. Science 2015;347:185-8.
13. Kakarougkas A, Jeggo PA.DNA DSB repair pathway choice: An orchestrated handover mechanism. Br J Radiol 2014;87:20130685.
14. Dueva R, Iliakis G. Alternative pathways of non-homologous end joining (NHEJ) in genomic instability and cancer. Transl Cancer Res 2013;2: 163-77.
15. Caldecott KW. DNA single-strand break repair. Exp Cell Res 2014;329:2-8.
16. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004; 432:316-23.
17. Olson E, Nievera CJ, Liu E, Lee AY, Chen L, Wu X. The Mre11 complex mediates the S-phase checkpoint through an interaction with replication protein A. Mol Cell Biol 2007;27:6053-67.
18. Falck J, Petrini JH, Williams BR, Lukas J, Bartek J. The DNA damagedependent intra-S phase checkpoint is regulated by parallel pathways. Nat Genet 2002;30:290-4.
19. Riabinska A, Daheim M, Herter-Sprie GS, Winkler J, Fritz C, Hallek M, et al. Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors. Science Transl Med 2013;5:189ra78.
20. Reaper PM, Griffiths MR, Long JM, Charrier JD, Maccormick S, Charlton PA, et al. Selective killing of ATM-or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol 2011;7:428-30.
21. Mohni KN, Kavanaugh GM, Cortez D. ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency. Cancer Res 2014;74: 2835-45.
22. Karlin JD, Tokarz M, Beckta J, Farhan A, Pike K, Barlaam B, et al. A novel ATM kinase inhibitor effectively radiosensitizes glioblastoma inmice. Int J Radiat Oncol Biol Phys 90:S35.
23. Fokas E, Prevo R, Pollard JR, Reaper PM, Charlton PA, Cornelissen B, et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis 2012;3: e441.
24. Srivastava M, Nambiar M, Sharma S, Karki SS, Goldsmith G, HegdeM, et al. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell 2012;151:1474-87.
25. Senra JM, Telfer BA, Cherry KE, McCrudden CM, Hirst DG, O'Connor MJ, et al. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol Cancer Ther 2011;10:1949-58.
26. Bridges KA, Hirai H, Buser CA, Brooks C, Liu H, Buchholz TA, et al. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res 2011;17:5638-48.
27. Mitchell JB, Choudhuri R, Fabre K, Sowers AL, Citrin D, Zabludoff SD, et al. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res 2010;16:2076-84.
28. Vance S, Parsels LA, Parsels JD, Maybaum J, Lawrence T, Morgan MA. Radiosensitization of pancreatic cancer cells by combined Chk1 and PARP1 inhibition using AZD7762 and olaparib [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, Florida. Philadelphia (PA): AACR; 2011. Abstract nr 2657.
29. Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC, et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 2010;70:4972-81.
30. Karnak D, Engelke CG, Parsels LA, Kausar T, Wei D, Robertson JR, et al. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. Clin Cancer Res 2014;20:5085-96.
31. Krajewska M, Heijink AM, Bisselink YJ, Seinstra RI, Sillje HH, de Vries EG, et al. Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination. Oncogene 2013;32:3001-8.
32. Biddlestone-Thorpe L, Sajjad M, Rosenberg E, Beckta JM, Valerie NC, TokarzM, et al.ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation. Clin Cancer Res 2013;19:3189-200.
33. Loser DA, Shibata A, Shibata AK, Woodbine LJ, Jeggo PA, Chalmers AJ. Sensitization to radiation and alkylating agents by inhibitors of poly(ADPwwwribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol Cancer Ther 2010;9:1775-87.
34. Bridges KA, Toniatti C, Buser CA, Liu H, Buchholz TA, Meyn RE. Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells. Oncotarget 2014; 5:5076-86.
35. Chalmers AJ, Lakshman M, Chan N, Bristow RG. Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Semin Radiat Oncol 2010;20:274-81.
36. Neijenhuis S, Verwijs-Janssen M, van den Broek LJ, Begg AC, Vens C. Targeted radiosensitization of cells expressing truncated DNA polymerase {beta}. Cancer Res 2010;70:8706-14.
37. Budke B, Logan HL, Kalin JH, Zelivianskaia AS, Cameron McGuire W, Miller LL, et al. RI-1: A chemical inhibitor of RAD51 that disrupts homologous recombination in human cells. Nucleic Acids Res 2012;40:7347-57.
38. Huang F, Mazin AV. A small molecule inhibitor of human RAD51 potentiates breast cancer cell killing by therapeutic agents in mouse xenografts. PLoS ONE 2014;9:e100993.
39. Starcevic D, Dalal S, Sweasy JB. Is there a link between DNA polymerase beta and cancer? Cell Cycle 2004;3:998-1001.
40. Gilad O, Nabet BY, Ragland RL, Schoppy DW, Smith KD, Durham AC, et al. Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res 2010;70:9693-702.
41. Grabocka E, Pylayeva-Gupta Y, Jones MJ, Lubkov V, Yemanaberhan E, Taylor L, et al. Wild-Type H-And N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response. Cancer Cell 2014;25:243-56.
42. Rohban S, Campaner S. Myc induced replicative stress response: how to cope with it and exploit it. Biochim Biophys Acta 2015;1849:517-24.
43. Murga M, Campaner S, Lopez-Contreras AJ, Toledo LI, Soria R, Montana MF, et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol 2011;18: 1331-5.
44. MorganMA, Parsels LA, Maybaum J, Lawrence TS. Improving the efficacy of chemoradiation with targeted agents. Cancer Discov 2014;4:280-91.
45. Frank AO, Feldkamp MD, Kennedy JP, Waterson AG, Pelz NF, Patrone JD, et al. Discovery of a potent inhibitor of replication protein a proteinprotein interactions using a fragment-linking approach. J Med Chem 2013;56:9242-50.
46. Glanzer JG, Liu S, Wang L, Mosel A, Peng A, Oakley GG. RPA inhibition increases replication stress and suppresses tumor growth. Cancer Res 2014;74:5165-72.
47. Neher TM, Bodenmiller D, Fitch RW, Jalal SI, Turchi JJ. Novel irreversible small molecule inhibitors of replication protein A display single-Agent activity and synergize with cisplatin. Mol Cancer Ther 2011;10:1796-806.
48. Hemann MT. From breaking bad to worse: exploiting homologous DNA repair deficiency in cancer. Cancer Discov 2014;4:516-8.
49. Willers H, Taghian AG, Luo CM, Treszezamsky A, Sgroi DC, Powell SN. Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies. Mol Cancer Res 2009;7:1304-9.
50. Naipal KA, Verkaik NS, AmezianeN, van Deurzen CH, Ter Brugge P, Meijers M, et al. Functional ex vivo assay to select homologous recombinationdeficient breast tumors for PARP inhibitor treatment. Clin Cancer Res 2014;20:4816-26.
51. Slyskova J, Korenkova V, Collins AR, Prochazka P, Vodickova L, Svec J, et al. Functional, genetic, and epigenetic aspects of base and nucleotide excision repair in colorectal carcinomas. Clin Cancer Res 2012;18:5878-87.
52. Schuler N, Palm J, Kaiser M, Betten D, Furtwangler R, Rube C, et al. DNAdamage foci to detect and characterize DNA repair alterations in children treated for pediatric malignancies. PLoS ONE 2014;9:e91319.
53. Nowsheen S, Cooper T, Stanley JA, Yang ES. Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells. PLoS ONE 2012;7:e46614.
54. Ibrahim YH, Garcia-Garcia C, Serra V, He L, Torres-Lockhart K, Prat A, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2012;2:1036-47.
55. Dungey FA, Caldecott KW, Chalmers AJ. Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. Mol Cancer Ther 2009;8:2243-54.
56. Vance S, Liu E, Zhao L, Parsels JD, Parsels LA, Brown JL, et al. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1. Cell Cycle 2011;10:4321-9.
57. Lu HR, Wang X, Wang Y. A stronger DNA damage-induced G2 checkpoint due to over-Activated CHK1 in the absence of PARP-1. Cell Cycle 2006; 5:2364-70.
58. Cremona CA, Behrens A. ATM signalling and cancer. Oncogene 2014;33: 3351-60.